the **SUPPLEMENTARY INFORMATION** section for electronic access to the draft guidance document.

**FOR FURTHER INFORMATION CONTACT:** Mai Huynh, Center for Veterinary Medicine (HFV–142), Food and Drug Administration, 7500 Standish Place, Rockville, MD 20855, 240–402–0669, *Mai.Huynh@fda.hhs.gov*

**SUPPLEMENTARY INFORMATION:**

## I. Background

FDA is announcing the availability of a draft GFI #115 (VICH GL22) entitled ''Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Reproduction Testing (Revision 1).'' This draft revised guidance has been developed for veterinary use by the VICH. In order to establish the safety of veterinary drug residues in human food, a number of toxicological evaluations are recommended including the assessment of any effects on reproduction. The objective of this guidance is to ensure international harmonization of reproduction testing that is appropriate for the evaluation of effects on reproduction from long-term, low-dose exposures; these effects may be encountered from the presence of veterinary drug residues in food.

FDA has participated in efforts to enhance international harmonization and is committed to seeking scientifically based harmonized technical procedures for pharmaceutical development. One of the goals of harmonization is to identify, and then reduce, differences in technical requirements for drug development among regulatory agencies in different countries. FDA has actively participated in the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use to develop harmonized technical requirements for the approval of human pharmaceutical and biological products among the European Union, Japan, and the United States. The VICH is a parallel initiative for veterinary medicinal products. The goal of the VICH is to develop harmonized technical requirements for the approval of veterinary medicinal products in the European Union, Japan, and the United States, and receives input from both regulatory and industry representatives.

The VICH Steering Committee is composed of member representatives from the European Commission and European Medicines Agency; AnimalhealthEurope; FDA—Center for Veterinary Medicine and U.S. Department of Agriculture—Center for Veterinary Biologics; the U.S. Animal Health Institute; the Japanese Ministry of Agriculture, Forestry and Fisheries; and the Japanese Veterinary Products Association. There are 10 observers to the VICH Steering Committee: one representative from government and one representative from industry of Australia, New Zealand, Canada, South Africa, and the United Kingdom. The World Organisation for Animal Health is an associate member of the VICH. The VICH Secretariat, which coordinates the preparation of documentation, is provided by HealthforAnimals.

This level 1 draft guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent the current thinking of FDA on ''Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Reproduction Testing (Revision 1).'' It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations.

## II. Paperwork Reduction Act of 1995

While this guidance contains no collection of information, it does refer to previously approved FDA collections of information. The previously approved collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501–3521). The collections of information in 21 CFR part 514 have been approved under OMB control numbers 0910–0032.

## III. Electronic Access

Persons with access to the internet may obtain the draft guidance at *https://www.fda.gov/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/default.htm, https://www.fda.gov/regulatory-information/search-fda-guidance-documents,* or *https://www.regulations.gov.*

Dated: May 20, 2024.

**Lauren K. Roth,**

*Associate Commissioner for Policy.*

[FR Doc. 2024–11313 Filed 5–22–24; 8:45 am]

**BILLING CODE 4164–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Meeting of the National Vaccine Advisory Committee

**AGENCY:** Office of Infectious Disease and HIV/AIDS Policy, Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services.

**ACTION:** Notice.

**SUMMARY:** As stipulated by the Federal Advisory Committee Act, the Department of Health and Human Services (HHS) hereby gives notice that the National Vaccine Advisory Committee (NVAC) will hold an in-person meeting. The meeting will be open to the public and public comment will be heard during the meeting.

**DATES:** The meeting will be held June 13–14, 2024. The confirmed meeting times and agenda will be posted on the NVAC website at *http://www.hhs.gov/nvpo/nvac/meetings/index.html* as soon as they become available.

**ADDRESSES:** Instructions regarding attending this meeting will be posted online at: *http://www.hhs.gov/nvpo/nvac/meetings/index.html* at least one week prior to the meeting. Pre-registration is required for those who wish to attend the meeting in person or participate in public comment. Please register at *http://www.hhs.gov/nvpo/nvac/meetings/index.html.*

**FOR FURTHER INFORMATION CONTACT:** Ann Aikin, Acting Designated Federal Officer, Office of Infectious Disease and HIV/AIDS Policy, U.S. Department of Health and Human Services, Tower Building, Room, 1101 Wootton Parkway, Rockville, MD 20852. Email: *nvac@hhs.gov.* Phone: 202–795–7697.

**SUPPLEMENTARY INFORMATION:** Pursuant to section 2101 of the Public Health Service Act (42 U.S.C. 300aa–1), the Secretary of HHS was mandated to establish the National Vaccine Program to achieve optimal prevention of human infectious diseases through immunization and to achieve optimal prevention against adverse reactions to vaccines. The NVAC was established to provide advice and make recommendations to the Director of the National Vaccine Program on matters related to the Program's responsibilities. The Assistant Secretary for Health serves as Director of the National Vaccine Program.

During this meeting, NVAC will hear presentations to support the recent charge on innovation from Admiral Rachel L. Levine, MD, the Assistant Secretary for Health and Director of the National Vaccine Program. NVAC will also hear presentations on recent surges in measles cases, tuberculosis and breast cancer vaccines in development, and mpox vaccination activities. Speakers will also discuss progress and priorities for the upcoming *Vaccines National Strategic Plan.* Global immunization and data modernization efforts will also

be reviewed during the meeting. Please note that agenda items are subject to change, as priorities dictate. Information on the final meeting agenda will be posted prior to the meeting on the NVAC website: *http://www.hhs.gov/nvpo/nvac/index.html.*

Members of the public will have the opportunity to provide comment at the NVAC meeting during the public comment period designated on the agenda. Public comments made during the meeting will be limited to three minutes per person to ensure time is allotted for all those wishing to speak. Members of the public may also submit written comments. Written comments should not exceed three pages in length. Individuals planning to submit comments should email their written comments or their request to provide a comment during the meeting to *nvac@hhs.gov* at least five business days prior to the meeting.

Dated: May 7, 2024.

**Ann Aikin,**

*Acting Designated Federal Official, Office of the Assistant Secretary for Health.*

[FR Doc. 2024–11274 Filed 5–22–24; 8:45 am]

**BILLING CODE 4150–44–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Meeting of the Presidential Advisory Council on HIV/AIDS

**AGENCY:** Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services.

**ACTION:** Notice of a meeting.

**SUMMARY:** As stipulated by the Federal Advisory Committee Act, the U.S. Department of Health and Human Service is hereby giving notice that the Presidential Advisory Council on HIV/AIDS (PACHA or the Council) will convene the 81st full council meeting on Wednesday, June 5–Thursday, June 6, 2024. The meeting will include panels on the state of HIV science; agencies' perspectives on ending the HIV epidemic; State-level system approaches from health departments; and anti-LGBTQI+ laws and their impact nationally & globally. It will be open to the public and there will be a public comment session during the meeting; pre-registration is required to provide public comment. To pre-register to provide public comment, please send an email to *PACHA@hhs.gov* and include your name, organization, and title by close of business Tuesday, May 28, 2024. If you decide you would like to provide public comment but do not pre-register, you may submit your written statement by emailing *PACHA@hhs.gov* by close of business Thursday, June 13, 2024. The meeting agenda will be posted on the PACHA page on *HIV.gov* at *https://www.hiv.gov/federal-response/pacha/about-pacha* prior to the meeting.

**DATES:** The meeting will convene on Wednesday, June 5, 2024 from approximately 9 a.m. to 5 p.m. (ET) and Thursday, June 6, 2024 from approximately 9 a.m. to 4 p.m. (ET).

**ADDRESSES:** DoubleTree Crystal City Hotel, 300 Army Navy Dr., Arlington, Virginia 22202. To attend the meeting virtually, please visit *www.hhs.gov/live.*

**FOR FURTHER INFORMATION CONTACT:** Ms. Chloe Loving, MPH, Committee Manager for PACHA, at *PACHA@hhs.gov* or 202–795–7697. Additional information can be obtained by accessing the Council's page on the *HIV.gov* site at *www.hiv.gov/pacha.*

**SUPPLEMENTARY INFORMATION:** PACHA was established by Executive Order 12963, dated June 14, 1995, as amended by Executive Order 13009, dated June 14, 1996 and is currently operating under the authority given in Executive Order 14109, dated September 29, 2023. The Council was established to provide advice, information, and recommendations to the Secretary regarding programs and policies intended to promote effective HIV diagnosis, treatment, prevention, and quality care services. The functions of the Council are solely advisory in nature.

The Council consists of not more than 35 members. Council members are selected from prominent community leaders with particular expertise in, or knowledge of, matters concerning HIV and AIDS, public health, global health, population health, philanthropy, marketing or business, as well as other national leaders held in high esteem from other sectors of society. PACHA selections also include persons with lived HIV experience and persons disproportionately affected by HIV. Council members are appointed by the Secretary.

Dated: May 15, 2024.

**Caroline Talev,**

*Executive Director, Presidential Advisory Council on HIV/AIDS, Senior Management Analyst, Office of Infectious Disease and HIV/AIDS Policy, Office of the Assistant Secretary for Health, Department of Health and Human Services.*

[FR Doc. 2024–11369 Filed 5–22–24; 8:45 am]

**BILLING CODE 4150–43–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Advisory Committee on Seniors and Disasters Meeting Notice; Cancellation

**AGENCY:** National Advisory Committee on Seniors and Disasters (NACSD), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS).

**ACTION:** Notice; cancellation of meeting.

**SUMMARY:** The Administration for Strategic Preparedness and Response (ASPR) published a notice in the **Federal Register** concerning a public meeting of the National Advisory Committee on Seniors and Disasters (NACSD). The public meeting, scheduled for Monday, May 20, 2024, at 2:30 p.m. ET, has been cancelled and will be rescheduled for a later date. The notice is in the **Federal Register** on Thursday, May 2, 2024, in FR Document Number 2024–09584 on pages 35843–35844 (2 pages).

**FOR FURTHER INFORMATION CONTACT:** Dr. Maxine Kellman; NACSD Designated Federal Official, at *NACSD@HHS.GOV* or (202) 260–0047.

The Administrator and Assistant Secretary for Preparedness and Response of ASPR, Dawn O'Connell, having reviewed and approved this document, authorizes Mary Radebach, who is the **Federal Register** Liaison, to electronically sign this document for purposes of publication in the **Federal Register**.

Dated: May 17, 2024.

**Mary Radebach,**

*Federal Register Liaison, Administration for Strategic Preparedness and Response.*

[FR Doc. 2024–11297 Filed 5–22–24; 8:45 am]

**BILLING CODE 4150–37–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Announcing the Call for Nominations for the 2024 President's Council on Sports, Fitness & Nutrition Awards

**AGENCY:** Office of Disease Prevention and Health Promotion, Office of the Assistant Secretary for Health, Office of the Secretary, U.S. Department of Health and Human Services.

**ACTION:** Notice.

**SUMMARY:** The President's Council on Sports, Fitness & Nutrition (Council or PCSFN) is calling for nominations from the public for its three awards—the Lifetime Impact Award, the Community